API, or active pharmaceutical ingredient, refers to the ingredients found in capsules and other pharmaceutical drugs. These ingredients show the intended effect on the body. The API has two categories: synthetic and biotech APIs. The synthetic APIs are known as small molecules, and constitute a large part of the pharmaceutical market, with many small molecule drugs commercially available on the market. Biotech or natural APIs are used in the making of biologics, which are increasingly becoming the top-selling drugs. Most of the drugs that are available now on the market are synthetic drugs. Also, biotech drugs are gaining ground slowly and steadily.
According to Actual Market Research, "Saudi Arabia Active Pharmaceutical Ingredient Market Overview, 2027," the Saudi Arabian market for API is examined on the basis of synthesis, therapeutic application, and manufacturer type. The synthesis type has the biotech API progressively gaining ground with a CAGR of nearly 8%. Whereas by therapeutic application, the market size of oncology diseases is observing growth in terms of CAGR. This increase in market share can help the company to create a cost advantage in comparison to that of competitors. Also, this can be considered more profitable for the companies operating in the market. However, on the other hand, by manufacturer type, the captive API is more dominating because of the investments in the manufacturing facilities of the API drugs. The merchant API, on the other hand, is gradually gaining ground for the API market size along with the growth of synthetic API.
The most common diseases in Saudi Arabia are heart diseases, or cardiovascular diseases, diabetes, and kidney diseases. Amongst these, heart disease is the leading cause of death, at around 29%. On the other hand, diabetes is the most common disease in Saudi Arabia. And kidney disease has an estimation of around 9092 per 100,000 populations, which is estimated to be more than Western Europe. To decrease these numbers, the country imports the required APIs in order to prepare the drugs and cure these diseases. The country is being observed to be more biased towards the local players. To protect the interests of the local players, the country is imposing higher prices on the foreign players. Moreover, the API market is expected to see growth in the upcoming years with a CAGR of 6.32%.
The outbreak of COVID-19 is considered the most common communicable disease that had a market of around 0.190 USD in the previous years. The number of deaths and the cases during COVID were around 9100 and the cases were around 7.67L. However, the API market is mostly driven by oncology and diabetes. According to the sources, around 7 million of the population are diabetic and another 3 million are pre-diabetic. Therefore, the API market through diabetes applications has raised the bar in terms of CAGR. Oncology or cancer has a case of around a 5-year prevalence amongst women of 43.4 thousand, compared to 39.2 thousand in men. In comparison to the previous year, the therapeutic application of oncology diseases has the largest market share. The major consumption of the API was increased because of the novel coronavirus. By looking at the impact of novel coronaviruses, the Saudi government led to the identification of the required APIs and they were approved by the legal authorities. This led to the increased production of pharmaceutical drugs to cure the diseases. Therefore, this COVID-19 reason is stated to be one of the major reasons for the increased consumption of the APIs.
Considered in this report
• Geography: Saudi Arabia
• Historic Year: 2016
• Base year: 2021
• Estimated year: 2022
• Forecast year: 2027
Aspects covered in this report
• Saudi Arabia active pharmaceutical ingredient market
• Application wise API market analysis
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation
Based on synthesis type of API in the report:
• Synthetic API
• Biotech API
Based on therapeutic application type of API in the report:
• Communicable diseases
• Oncology
• Diabetes
• Cardiovascular diseases
• Pain management
• Respiratory diseases
• Other therapeutic application
By Type of manufacturer in the report:
• Captive API
• Biotech API
The approach of the report:
This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and listing out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, annual report of companies, analysing the government generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducted trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers in regional aspects, tier aspects, age group, and gender. Once we have primary data with us we have started verifying the details obtained from secondary sources.
Intended audience
This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to API market industry, Medical industry, and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.
Asia-Pacific dominates the market and is the largest and fastest-growing market in the animal growth promoters industry globally
Download Sample
We are friendly and approachable, give us a call.